Clinical Pharmacology and Pharmacy, 2018 (vol. 32), issue 1
Original articles
Prednisolone as a sample of the substance selected for Medical Literature Monitoring
Jaroslav Horký
Klin Farmakol Farm. 2018;32(1):3-7 | DOI: 10.36290/far.2018.001 
Prednisolone belongs to most frequently reported substances in Medical Literature Monitoring (MLM) provided by EuropeanMedicines Agency since September 2015. The official list of MLM substances includes not only prednisolone, but also methylprednisoloneunder the item PREDNISOLONE. However in fact, introducing and classification of methylprednisolone under the itemof prednisolone is not careful and reliable and many relevant case reports are missing in MLM. On the contrary, some articleswith prednisone are incorrectly labelled under prednisolone. Concrete examples are given in this article.
Main topic
Novel treatment options for anaemia in patients with chronic kidney disease
Romana Ryšavá
Klin Farmakol Farm. 2018;32(1):8-13 | DOI: 10.36290/far.2018.002
Anaemia is a very common complication of chronic kidney disease (CKD) and renal failure. Since the introduction of ESAs (erythropoiesis-stimulating agents) in the clinical practice, the view of anaemia treatment has changed considerably and, currently, thetreatment safety is preferred to complete correction of anaemia. In addition to ESAs, a wide range of novel agents developed inorder to favourably affect erythropoiesis have recently been tested. They include, in particular, HIF-stabilizers (roxadustat, molidustat,vadadustat, and daprodustat), sotatercept, or GATA2 inhibitors. The requirements for treatment safety were the reasonfor the conduction...
Drug-induced nephropathy
Markéta Kolečková, Tomáš Tichý
Klin Farmakol Farm. 2018;32(1):14-19 | DOI: 10.36290/far.2018.003
The kidneys are a frequent target of both acute and chronic drug-induced injury because of their concentration and eliminationfunction. However, mechanisms of their nephrotoxicity vary in dependence on the drug group. Histological verification,along with a history of pharmacological therapy, is still regarded as a gold standard of diagnostic process. From a pathologicalpoint of view, all the structures of the renal parenchyma may be involved. In the majority of cases the involvement of renaltubules and interstitium is observed, characterized by the image of ischemic and nephrotoxic acute tubular necrosis, acuteor chronic tubulointerstitial nephritis...
Renoprotective effects of gliflozins
Jan Vachek, Vladimír Tesař
Klin Farmakol Farm. 2018;32(1):20-21 | DOI: 10.36290/far.2018.004
Cardiovascular diseases are the leading cause of morbidity and mortality in patients with type 2 diabetes mellitus (T2DM). Theirlikelihood is further increased by the presence of diabetic kidney disease which develops in up to 40% of patients with T2DM.In the EMPA REG OUTCOME trial, which was a large randomized, placebo-controlled study, empagliflozin, an inhibitor of sodium-glucose cotransporter 2 (SGLT-2), was shown to have an effect on cardiovascular morbidity and mortality and on exacerbationof nephropathy; the study included patients with a high risk of cardiovascular events. Recently, cardio- and nephroprotectiveeffects have also been demonstrated...
Review articles
Calcium channel blockers after 50 years
Jiří Špác, Markéta Vyskočilová
Klin Farmakol Farm. 2018;32(1):22-26 | DOI: 10.36290/far.2018.005
Calcium channel blockers (CCBs) were initially developed in the 1960 and are now among the most frequently prescribed drugsfor the treatment of cardiovascular diseases. CCBs inhibit the inward-flow of calcium ions causing systemic vasodilation. They areused in the treatment of various cardiovascular diseases including angina pectoris, hypertension, cardiac arrhythmias and may bebeneficial in patients with pulmonary hypertension and Raynaud’s phenomenon. There are three classes of CCBs: dihydropyridine(DHP), phenylalkylamine and benzothiazepine derivatives. These classes differ in chemical structure and binding sites resulting indiffering cardiac...
Metformin: an old substance – new indications
Eva Račická
Klin Farmakol Farm. 2018;32(1):27-30 | DOI: 10.36290/far.2018.006
Year 2017 is the year of 60th anniversary of first clinical use of metformin for diabetes. During the era of its use metformin hasproved ability to counter insulin resistence and decrease hyperglycaemia without weight gain and increased risk of hypoglycaemia,its long-term cardiovascular benefit was identified by the UK Prospective Diabetes Study in 1998 and resulted in placementof metformin as initial therapy to manage hyperglycaemia in type 2. diabetes. In 2016 FDA and EMA changed the labelling of allmetformin-containing medication for use with mild and moderate impairment in kidney function with definition of apropriatedoses and contraindications....
Case report
Treatment and nursing of venous ulcers using wet methods of therapy
Andrea Šuličová, Tatiana Šantová, Jana Cinová, Iveta Ondriová, Zuzana Novotná, Zuzana Šimová
Klin Farmakol Farm. 2018;32(1):31-35 | DOI: 10.36290/far.2018.007
84-year old patient treated at the dermatology clinic in 2002 with a diagnosis of venous leg ulcers l. dx. The patient has a positivefamily history. She came with three weeks opened defect of the right tibia, which originated getting hit right leg, followedby increasing the wound. She was treated six years for venous leg ulcers on the right leg mostly conventional therapy. In 2008,the defect healed completely. Right tibia puncture was re-opened in 2012 and diagnosed with recurrent venous leg ulcers l. dx.Treatment was initiated by modern method – moist wound healing, because of developed defect located on the sclerotic surface.Treatment is stagnating,...